dc.contributor.author | Nikolopoulos, Georgios K. | en |
dc.contributor.author | Tsiodras, Sotirios | en |
dc.contributor.author | Bonovas, Stefanos | en |
dc.contributor.author | Hatzakis, A. | en |
dc.creator | Nikolopoulos, Georgios K. | en |
dc.creator | Tsiodras, Sotirios | en |
dc.creator | Bonovas, Stefanos | en |
dc.creator | Hatzakis, A. | en |
dc.date.accessioned | 2018-06-22T09:54:11Z | |
dc.date.available | 2018-06-22T09:54:11Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42226 | |
dc.description.abstract | Infection with Human Immunodeficiency Virus (HIV) remains a global public health problem. Although the epidemic has not been completely controlled, there was considerable progress in HIV prevention and treatment during the last 30 years. The modern prevention approaches are multi-component including also the administration of combinations of potent antiretroviral agents as a prophylaxis after occupational or non-occupational exposures to HIV. The aim of the current review is to present the chemical and pharmacological characteristics of antiretroviral drugs used in HIV prophylaxis and to describe briefly the medical management of exposures to potentially infectious body fluids. | en |
dc.language.iso | eng | en |
dc.source | Current medicinal chemistry | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Abdominal pain | en |
dc.subject | Anemia | en |
dc.subject | Anorexia | en |
dc.subject | Diarrhea | en |
dc.subject | Drug efficacy | en |
dc.subject | Fatigue | en |
dc.subject | Myalgia | en |
dc.subject | Neutropenia | en |
dc.subject | Pregnant woman | en |
dc.subject | Lamivudine | en |
dc.subject | Teratogenicity | en |
dc.subject | Zidovudine | en |
dc.subject | Side effect | en |
dc.subject | Vomiting | en |
dc.subject | Nausea | en |
dc.subject | Drug clearance | en |
dc.subject | Hiv infections | en |
dc.subject | Virus transmission | en |
dc.subject | Hyperbilirubinemia | en |
dc.subject | Pancreatitis | en |
dc.subject | Depression | en |
dc.subject | Peripheral neuropathy | en |
dc.subject | Deoxycytidine | en |
dc.subject | Recommended drug dose | en |
dc.subject | Drug blood level | en |
dc.subject | Drug half life | en |
dc.subject | Dizziness | en |
dc.subject | Insomnia | en |
dc.subject | Flatulence | en |
dc.subject | Somnolence | en |
dc.subject | Infection prevention | en |
dc.subject | Gastrointestinal tract | en |
dc.subject | Cholesterol blood level | en |
dc.subject | Triacylglycerol blood level | en |
dc.subject | Neuropathy | en |
dc.subject | Rash | en |
dc.subject | Taste disorder | en |
dc.subject | Hiv | en |
dc.subject | Paresthesia | en |
dc.subject | Single drug dose | en |
dc.subject | Anti-hiv agents | en |
dc.subject | Occupational exposure | en |
dc.subject | Body weight | en |
dc.subject | Indinavir | en |
dc.subject | Abnormal dreaming | en |
dc.subject | Antiretrovirus agent | en |
dc.subject | Coughing | en |
dc.subject | Emtricitabine | en |
dc.subject | Tenofovir disoproxil | en |
dc.subject | Virus replication | en |
dc.subject | Prophylaxis | en |
dc.subject | Tenofovir | en |
dc.subject | Exposure | en |
dc.subject | Antiretrovirals | en |
dc.subject | Atazanavir | en |
dc.subject | Efavirenz | en |
dc.subject | Human immunodeficiency virus 1 infection | en |
dc.subject | Lopinavir plus ritonavir | en |
dc.subject | Nelfinavir | en |
dc.subject | Nevirapine | en |
dc.subject | Ritonavir | en |
dc.subject | Saquinavir | en |
dc.subject | Virus dna | en |
dc.subject | Abacavir | en |
dc.subject | Adenine | en |
dc.subject | Antiviral activity | en |
dc.subject | Bacterial pneumonia | en |
dc.subject | Body fluid | en |
dc.subject | Concentration loss | en |
dc.subject | Cytochrome p450 2b6 | en |
dc.subject | Cytochrome p450 2c19 | en |
dc.subject | Cytochrome p450 3a | en |
dc.subject | Cytochrome p450 3a4 | en |
dc.subject | Didanosine | en |
dc.subject | Dideoxynucleosides | en |
dc.subject | Drug absorption | en |
dc.subject | Drug bioavailability | en |
dc.subject | Drug induced headache | en |
dc.subject | Enfuvirtide | en |
dc.subject | Fosamprenavir | en |
dc.subject | Gag protein | en |
dc.subject | Hla b antigen | en |
dc.subject | Hyperglycemia | en |
dc.subject | Injection site reaction | en |
dc.subject | Lactic acidosis | en |
dc.subject | Liver function test | en |
dc.subject | Nephrolithiasis | en |
dc.subject | Non-occupational | en |
dc.subject | Occupational | en |
dc.subject | Organophosphonates | en |
dc.subject | Protein binding | en |
dc.subject | Stavudine | en |
dc.subject | Stevens johnson syndrome | en |
dc.subject | Vertical transmission | en |
dc.subject | Weakness | en |
dc.title | Antiretrovirals for HIV exposure prophylaxis | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.2174/092986712804485854 | |
dc.description.volume | 19 | |
dc.description.issue | 35 | |
dc.description.startingpage | 5924 | |
dc.description.endingpage | 5939 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Nikolopoulos, Georgios K.[0000-0002-3307-0246] | |
dc.contributor.orcid | Bonovas, Stefanos [0000-0001-6102-6579] | |
dc.contributor.orcid | Tsiodras, Sotirios [0000-0002-0463-4321] | |
dc.gnosis.orcid | 0000-0002-3307-0246 | |
dc.gnosis.orcid | 0000-0001-6102-6579 | |
dc.gnosis.orcid | 0000-0002-0463-4321 | |